As a Free StocksGuide user, you can view scores for all 7,025 stocks worldwide.
7 Analysts have issued a Avenue Therapeutics, Inc. forecast:
7 Analysts have issued a Avenue Therapeutics, Inc. forecast:
Mar '25 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | -9.49 -9.49 |
20%
20%
|
Net Profit | -9.16 -9.16 |
28%
28%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Avenue Therapeutics, Inc. engages in acquiring, licensing, developing, and commercializing products for use in the intensive care hospital setting. It focuses on the development of intravenous tramadol, which is intended for the treatment of moderate to moderately severe post-operative pain. The company was founded on February 9, 2015 and is headquartered in New York, NY.
Head office | United States |
CEO | Alexandra MacLean |
Employees | 2 |
Founded | 2015 |
Website | avenuetx.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.